Reported 139,210 shares, down 18,835 (11.9%) from the prior quarter.
Reported value 25.3%; share count -11.9% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-09-30 | 1070118 |
| 2023-12-31 | 0 |
| 2024-09-30 | 769656 |
| 2024-12-31 | 1265653 |
| 2025-03-31 | 1010272 |
| 2025-06-30 | 0 |
| 2025-09-30 | 1149452 |
| 2025-12-31 | 0 |
| 2026-03-31 | 1200016 |
| 2026-06-30 | 5721229 |
| 2026-09-30 | 7167923 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 139,210 | -18,835 (-11.9%) | 0.74% | $7,167,923 | 2026-11-16 | |
| Q2 2026 | Added | 158,045 | +109,422 (225.0%) | 0.51% | $5,721,229 | 2026-08-13 | |
| Q1 2026 | New | 48,623 | +48,623 (0.0%) | 0.14% | $1,200,016 | 2026-05-13 | |
| Q4 2025 | Reduced | 0 | -52,897 (-100.0%) | 0 | $0 | 2026-02-12 | |
| Q3 2025 | New | 52,897 | +52,897 (0.0%) | 0.13% | $1,149,452 | 2025-11-14 | |
| Q2 2025 | Reduced | 0 | -77,833 (-100.0%) | 0 | $0 | 2025-08-12 | |
| Q1 2025 | Reduced | 77,833 | -17,186 (-18.1%) | 0.17% | $1,010,272 | 2025-05-13 | |
| Q4 2024 | Reduced | 95,019 | -33,257 (-25.9%) | 0.18% | $1,265,653 | 2025-02-13 | |
| Q3 2024 | New | 128,276 | +128,276 (0.0%) | 0.12% | $769,656 | 2024-11-13 | |
| Q4 2023 | Reduced | 0 | -256,623 (-100.0%) | 0 | $0 | 2024-02-14 | |
| Q3 2023 | New | 256,623 | +256,623 (0.0%) | 0.21% | $1,070,118 | 2023-11-13 |
Who else reported the position
238 managers reported ETON PHARMACEUTICALS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| EcoR1 Capital LLC | Added | 2,470,920 | +298,982 | 5.65% | $127,227,671 | 9 qtrs |
| Opaleye Management Inc | Reduced | 2,440,000 | -420,000 | 14.15% | $125,635,600 | 32 qtrs |
| BlackRock Inc | Added | 2,095,914 | +200,081 | < 0.01% | $107,918,612 | 9 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 1,203,342 | +226,772 | < 0.01% | $61,960,080 | 3 qtrs |
| Nantahala Capital Management LLC | Reduced | 875,507 | -300,444 | 1.43% | $45,079,855 | 10 qtrs |
| FMR LLC | Added | 823,587 | +821,462 | < 0.01% | $42,406,452 | 7 qtrs |
| STATE STREET CORPORATION | Added | 775,543 | +73,757 | < 0.01% | $39,932,709 | 26 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 764,398 | +112,095 | < 0.01% | $39,368,003 | 26 qtrs |
| MORGAN STANLEY | Reduced | 513,174 | -254,798 | < 0.01% | $26,423,338 | 32 qtrs |
| OBERWEIS ASSET MANAGEMENT INC | Reduced | 500,403 | -1,197 | 0.58% | $25,765,750 | 5 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- Common Stock
Voting authority reported
- Sole
- 60,458
- Shared
- 0
- None
- 78,752
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.